Information about Pramlintide
Pramlintide is a recombinant DNA produced polypeptide analogue of human amylin that is used in combination with insulin in the therapy of diabetes.
Liver safety of Pramlintide
Pramlintide has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury.
Mechanism of action of Pramlintide
Pramlintide (pram' lin tide) is a synthetic analogue of human amylin that is used in combination with insulin in the treatment of diabetes. Amylin is a human pancreatic hormone which, like insulin, is produced in pancreatic beta cells and aids in the control of blood sugar after meals by delaying gastric emptying, decreasing glucagon secretion and suppressing appetite. The loss of beta cell function that occurs early in type 1 diabetes and late in type 2 diabetes leads to deficiency in amylin secretion. Pramlintide differs from human amylin in 3 of its 37 amino acids, modifications which allow for a longer half-life of the hormone.
FDA approval information for Pramlintide
Pramlintide was approved for use in diabetes as an adjunct to insulin therapy in the United States in 2005.
Brand name for Pramlintide
Pramlintide is available in solution in vials and pens for injection under the brand name Symlin.
Dosage and administration for Pramlintide
The typical starting dose in type 1 diabetes is 15 µg subcutaneously before each meal, with subsequent titration to a target dose of 60 µg before each meal. The recommended starting dose in type 2 diabetes is 60 µg, with a target maintenance dose of 120 µg subcutaneously before each meal.
Side effects of Pramlintide
Common side effects of pramlintide include nausea, vomiting, anorexia, fatigue, headache, dizziness and hypoglycemia. Severe adverse reactions include severe hypoglycemia, particularly in type 1 diabetes.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors